🚀Enjoy a 7-Day Free Trial Until Jul 19, 2024!

AT

Avenue Therapeutics IncNASDAQ ATXI Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ATXI undervalued compared to its fair value?

The fair value of ATXI stock is hidden USD. Relative to the market price of 3.48 USD Avenue Therapeutics Inc is hidden.

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Har...[More about valuation]

Avenue Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.003 $B

Price:

3.48 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

0.065

FINANCIALS

Avenue Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0021 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.0005 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.0005 B
-0.0037 B

Financial Position Analysis

Assets

0.0005 B
Current Assets
0.0005 B
Total non-current assets

Total current liabilities
0.005 B
Total non-current liabilities
-0.0009 B

Cash Flow Statement

-0.0009 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0009 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Avenue Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ATXI attractive for investment based on fundamental analysis?

ATXI stock rating is hidden. Avenue Therapeutics is a hidden by Eyestock methodology.

Get ATXI Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ATXI analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ATXI to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Avenue Therapeutics Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

Avenue Therapeutics Inc dividends

ATXI dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ATXI stock

About the company Avenue Therapeutics Inc

Market cap $B

0.003

Dividend yield

Shares outstanding

7.0232 B

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 4 full-time employees. The company went IPO on 2017-06-27. The firm seeks to develop and commercialize its product principally for use in the acute/intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. The company also works through the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. These opioid and non-opioid modes of action are synergistic, providing multimodal therapy with the use of a single drug. Tramadol is marketed as an oral agent indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Ultracet, a combination product containing tramadol and acetaminophen, is also marketed in the United States (Ortho-McNeil-Janssen).

ATXI profile

  • Ticker

    ATXI

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    27 June 2017

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    4

  • City

    Bay Harbor Islands

  • Address

    1111 Kane Concourse, Suite 301

  • Cusip

    05360L304